SHAREHOLDER INFORMATION Directors Corporate broker Auditor Bruno Angelici J. P. Morgan Cazenove KPMG LLP Non-Executive Chairman 25 Bank Street 15 Canada Square Canary Wharf London Frank Condella London E14 5GL, UK Non-Executive Vice Chairman E14 5JP, UK Bankers James Ward-Lilley Corporate broker Barclays Bank plc Chief Executive Officer Numis Securities Limited 28 Chesterton Road Andrew Derodra The London Stock Exchange Building Cambridge Chief Financial Officer 10 Paternoster Square CB4 3AZ, UK London Susan Foden Legal advisors EC4M 7LT, UK Non-Executive Director and Senior Clifford Chance Independent Director Public relations 10 Upper Bank Street Neil Warner Consilium Strategic Consulting Canary Wharf Non-Executive Director 41 Lothbury London London E14 5JJ, UK Dr Per-Olof Andersson EC2R 7HG, UK Non-Executive Director Vectura Group plc Registrars Registered office Thomas Werner Computershare Investor Services plc One Prospect West Non-Executive Director PO Box 82 Chippenham Juliet Thompson The Pavilions Wiltshire Non-Executive Director Bridgwater Road SN14 6FH, UK Bristol Company Secretary BS99 7NH, UK John Murphy Vectura trade marks Adept is a registered trade mark of Innovata Limited AKITA and FAVOLIR are registered trade marks of Activaero GmbH Clickhaler and Duohaler are registered trade marks of Innovata Biomed Limited.
These trade marks are in the process of being transferred to Tianjin Kinnovata Pharmaceutical Company Limited, in certain territories FOX is a trade mark of Vectura GmbH GyroHaler and Omnihaler are registered trade marks of Vectura Delivery Devices Limited PowderHale and Vectura are registered trade marks of Vectura Limited Third-party trade marks ADVATE and Extraneal are registered trade marks of Baxter International Inc. Anoro Ellipta, Relvar Ellipta Breo Ellipta and Incruse Ellipta are registered trade marks of GSK Breezhaler, Onbrez, Seebri Breezhaler, Ultibro Breezhaler and AirFluSal Forspiro are registered trade marks ofNovartis AG Bluetooth is a trade mark of Bluetooth SIG Forward-looking statement This Annual Report and Accounts contains forward-looking statements, including statements about the discovery, development and commercialisation of products.
Various risks may cause Vecturas actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes: failure to obtain patent protection for inventions: commercial limitations imposed by patents owned or controlled by third parties: dependence upon strategic alliance partners to develop and commercialise products and services: difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts: the requirement for substantial funding to conduct research and development and to expand commercialisation activities: and product initiatives by competitors.
As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements.
We disclaim any intention or obligation to update orrevise any forward-looking statements, whether as a result of new information, future events or otherwise.
156 Vectura Group plc Annual Report and Accounts 2017 Vectura Group plcs commitment to environmental issues is reflected in this annual report which has been printed on UPM Fine, made from an FSC certified material.
Printed in the UK by CPI colour using their environmental printing technology.
Both manufacturing mill and the printer are registered to the Environmental Management System ISO14001 and are Forest Stewardship Council FSC chain-of-custody certified.
Vectura Group plc Annual Report and Accounts 2017 Vectura Group plc One Prospect West Chippenham Wiltshire SN14 6FH United Kingdom T 44 0 1249 667700 F 44 0 1249 667701 www.
com Registered in England and Wales Number: 03418970
